Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-3512676 plus Paclitaxel/Carboplatin in Advanced NSCLC
NCT00254891Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2005
- Primary completion
- Jul 2008
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 26
01
Overview
A Phase 3 trial of agatolimod in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Nov 2005; status: terminated.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00254891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254891.